000			05287nam a22003855i 4500
988			_aEbook_one2one
999			_c81513 _d81513 _x1
001			81513
003			ES-MaUEC
005			20240611040137.0
007			cr nn 008mamaa
008			151001s2015 gw | s |||| 0|eng d
020			_a9783319228341
024	7		_a10.1007/978-3-319-22834-1 _2doi
040			_aES-MaUEC
050		4	_aQR400.2.E68 _bE67 2015 EB
082	0	4	_a614.5999
245	0	0	_aEpstein Barr Virus _nVolume 2 _pOne Herpes Virus : Many Diseases _cedited by Christian Münz
250			_a1st ed. 2015.
264		1	_aCham, Switzerland _bSpringer _c2015
300			_a1 recurso en línea (VI, 505 páginas) _b39 ilustraciones, 32 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aCurrent Topics in Microbiology and Immunology _x0070-217X _v391
505	0		_aPreface -- EBV latency -- Chap. 1. EBNA1 â€{u032F}ri Frappier, University of Toronto, Canada -- Chap. 2. EBNA2 and its coactivator EBNA-LP â€{u00A5}ttina Kempkes, Helmholtz Center Munich, Germany, and Paul D. Ling, Baylor College of Medicine, Houston, USA -- Chap. 3. The EBNA3 family: two oncoproteins and a tumour suppressor that are central to the biology of EBV in B cellsâ€{u0361}rtin J. Allday, Quentin Bazot and Robert E. White, Imperial College London, UK. Chap. 4. The latent membrane protein 1 (LMP1) â€{u0072}nd Kieser and Kai R. Sterz, Helmholtz Center Munich, Germany. Chap. 5. Latent membrane protein 2 (LMP2) â€{u03F3}man Cen and Richard Longnecker, Northwestern University, Chicago, USA. Chap. 6. EBV non-coding RNAs â€{u04A5}becca L. Skalsky and Bryan R. Cullen, Duke University, Durham, USA -- E. Lytic EBV infection -- 7. Viral entry â€{u0329}udmila S. Chesnokova, Ru Jiang1 and Lindsey M. Hutt-Fletcher, Louisiana State University, Shreveport, USA -- Chap. 8. Epstein Barr virus lytic cycle reactivation â€{u02A5}ssica McKenzie and Ayman El-Guindy, Yale University, New Haven, USA -- Immune responses to EBV -- Chap. 9. Innate immune recognition of EBV â€{u006E}na LÃ{uE96D}ann and David Nadal, University of ZÃ{u2A63}h, Switzerland and Martin Rowe, University of Birmingham, UK -- Chap. 10. Epstein-Barr virus specific humoral immune responses in health and disease â€{u02A1}ap M. Middeldorp, VU Medical Center, Amsterdam, The Netherlands -- Chap. 11. T cell responses to EBV â€{u006E}drew D. Hislop and Graham S. Taylor, University of Birmingham, UK -- Chap. 12. Immune evasion by Epstein Barr virus â€{u0361}aike E. Ressing, Michiel van Gent, Anna M. Gram, Marjolein Hooykaas, Sytse Piersma and Emmanuel Wiertz, Utrecht Medical Center, The Netherlands -- Animal models of EBV infection -- Chap. 13. Non-human primate lymphocryptoviruses: past, present, and futureâ€{u02A1}nine MÃ{u8960}and Fred Wang, Harvard University, Boston, USA. Chap.14. EBV infection of mice with reconstituted human immune system components â€èristian MÃ{uEEAC} University of ZÃ{u2A63}h, Switzerland -- Therapy of EBV associated diseases -- Chap. 15. Adoptive T cell immunotherapy â€{u04F4}ephen Gottschalk and Cliona Rooney, Baylor College of Medicine, Houston, USA -- Chap. 16. The Development of Prophylactic and Therapeutic EBV Vaccines â€ïrey Smith and Rajiv Khanna, Queensland Institute of Medical Research, Brisbane, Australia -- Chap. 17. The biology and clinical utility of EBV monitoring in bloodâ€{u02A5}nnifer Kanakry and Richard Ambinder, Johns Hopkins University, Baltimore, USA -- Index.
520			_aEpstein Barr virus (EBV) was discovered as the first human tumor virus around 50 years ago. Since its discovery in Burkittâ€{u382C}ymphoma it has been associated with various other malignancies, infectious mononucleosis and even autoimmune diseases. The two book volumes on EBV summarize the first 50 years of research on this tumor virus, starting with historical perspectives on discovery, oncogenicity and immune control, reviewing the role that the virus plays in the various associated diseases and concluding with a discussion on how the immune system keeps persistent EBV infection under control in healthy EBV carriers and can be used to treat EBV associated diseases. The respective 32 chapters are written by international experts from three continents for health care providers, biomedical researchers and patients that are affected by EBV. The assembled knowledge should help to understand EBV associated diseases better and to develop EBV specific vaccination in the near future.
650		7	_aInmunología _2embne _9138330
710	2		_aSpringerLink (Online service) _0Local _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729 _9106996
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-22834-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12901039 _b10-10-17 _c18-01-16
942			_2lcc _cLE
945			_aRC261-271 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11570659 _z06-04-17
988	0	0	_aEBOOK, EBSPRINGER, GOBI_sep2018
998			_aSI _a_alco _a_vill _b10/2018 _cm _dz _ef _feng _ggw _h0